The Effect of Lanreotide on Volume of Polycystic Liver and Kidney in Autosomal Dominant Polycystic Kidney Disease
The aim of this single center observational study is to assess the effect of lanreotide on
polycystic liver and kidney. This is achieved by assessing total liver and kidney volume,
and several urinary markers that could predict kidney damage or kidney dysfunction, such as
GFR, blood pressure, and urinary tubular damage markers and serum biomarker FGF23.
The investigators aim to include 43 patients affected by a polycystic liver due to ADPKD.
The duration of the trial will be 28 weeks. The treatment will be 24 weeks and the first
screening visit will take place four weeks before start of treatment. Eligible patients will
be invited to participate.
Observational Model: Cohort, Time Perspective: Prospective
Change in total liver volume between baseline and 24 weeks, as determined by CT volumetry
Joost PH Drenth, MD, PhD
Radboud University Hospital
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)